Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378528691> ?p ?o ?g. }
- W4378528691 endingPage "791" @default.
- W4378528691 startingPage "791" @default.
- W4378528691 abstract "Serious vision loss occurs in patients affected by chronically raised intraocular pressure (IOP), a characteristic of many forms of glaucoma where damage to the optic nerve components causes progressive degeneration of retinal and brain neurons involved in visual perception. While many risk factors abound and have been validated for this glaucomatous optic neuropathy (GON), the major one is ocular hypertension (OHT), which results from the accumulation of excess aqueous humor (AQH) fluid in the anterior chamber of the eye. Millions around the world suffer from this asymptomatic and progressive degenerative eye disease. Since clinical evidence has revealed a strong correlation between the reduction in elevated IOP/OHT and GON progression, many drugs, devices, and surgical techniques have been developed to lower and control IOP. The constant quest for new pharmaceuticals and other modalities with superior therapeutic indices has recently yielded health authority-approved novel drugs with unique pharmacological signatures and mechanism(s) of action and AQH drainage microdevices for effectively and durably treating OHT. A unique nitric oxide-donating conjugate of latanoprost, an FP-receptor prostaglandin (PG; latanoprostene bunod), new rho kinase inhibitors (ripasudil; netarsudil), a novel non-PG EP2-receptor-selective agonist (omidenepag isopropyl), and a form of FP-receptor PG in a slow-release intracameral implant (Durysta) represent the additions to the pharmaceutical toolchest to mitigate the ravages of OHT. Despite these advances, early diagnosis of OHT and glaucoma still lags behind and would benefit from further concerted effort and attention." @default.
- W4378528691 created "2023-05-28" @default.
- W4378528691 creator A5024909155 @default.
- W4378528691 date "2023-05-26" @default.
- W4378528691 modified "2023-10-14" @default.
- W4378528691 title "Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients" @default.
- W4378528691 cites W1129919997 @default.
- W4378528691 cites W129311030 @default.
- W4378528691 cites W1435846789 @default.
- W4378528691 cites W1497974870 @default.
- W4378528691 cites W1502766931 @default.
- W4378528691 cites W1514989952 @default.
- W4378528691 cites W1560008616 @default.
- W4378528691 cites W1591860484 @default.
- W4378528691 cites W1645822117 @default.
- W4378528691 cites W1663890339 @default.
- W4378528691 cites W168887062 @default.
- W4378528691 cites W1777198532 @default.
- W4378528691 cites W1842399002 @default.
- W4378528691 cites W1843851062 @default.
- W4378528691 cites W1872187949 @default.
- W4378528691 cites W1900705944 @default.
- W4378528691 cites W1964812077 @default.
- W4378528691 cites W1965637818 @default.
- W4378528691 cites W1967364872 @default.
- W4378528691 cites W1969078424 @default.
- W4378528691 cites W1970986444 @default.
- W4378528691 cites W1973239499 @default.
- W4378528691 cites W1979262434 @default.
- W4378528691 cites W1979997467 @default.
- W4378528691 cites W1987502158 @default.
- W4378528691 cites W1991380118 @default.
- W4378528691 cites W1993843299 @default.
- W4378528691 cites W2003306398 @default.
- W4378528691 cites W2007287124 @default.
- W4378528691 cites W2008057268 @default.
- W4378528691 cites W2010179280 @default.
- W4378528691 cites W2010438530 @default.
- W4378528691 cites W2015755427 @default.
- W4378528691 cites W2017204654 @default.
- W4378528691 cites W2020935669 @default.
- W4378528691 cites W2021307653 @default.
- W4378528691 cites W2021499247 @default.
- W4378528691 cites W2022279971 @default.
- W4378528691 cites W2022805799 @default.
- W4378528691 cites W2023529902 @default.
- W4378528691 cites W2025032550 @default.
- W4378528691 cites W2028098651 @default.
- W4378528691 cites W2030668552 @default.
- W4378528691 cites W2033224478 @default.
- W4378528691 cites W2034742711 @default.
- W4378528691 cites W2036481695 @default.
- W4378528691 cites W2036839884 @default.
- W4378528691 cites W2038407307 @default.
- W4378528691 cites W2047191461 @default.
- W4378528691 cites W2047692690 @default.
- W4378528691 cites W2049570329 @default.
- W4378528691 cites W2057983478 @default.
- W4378528691 cites W2059593140 @default.
- W4378528691 cites W2060184518 @default.
- W4378528691 cites W2060387702 @default.
- W4378528691 cites W2061207844 @default.
- W4378528691 cites W2061286464 @default.
- W4378528691 cites W2065774664 @default.
- W4378528691 cites W2071605868 @default.
- W4378528691 cites W2072112660 @default.
- W4378528691 cites W2072365851 @default.
- W4378528691 cites W2077037485 @default.
- W4378528691 cites W2079202995 @default.
- W4378528691 cites W2081557929 @default.
- W4378528691 cites W2081703291 @default.
- W4378528691 cites W2081861923 @default.
- W4378528691 cites W2083173584 @default.
- W4378528691 cites W2083336195 @default.
- W4378528691 cites W2084292803 @default.
- W4378528691 cites W2086321796 @default.
- W4378528691 cites W2088402556 @default.
- W4378528691 cites W2090272621 @default.
- W4378528691 cites W2091179633 @default.
- W4378528691 cites W2093683922 @default.
- W4378528691 cites W2097557041 @default.
- W4378528691 cites W2110127308 @default.
- W4378528691 cites W2110758538 @default.
- W4378528691 cites W2110897487 @default.
- W4378528691 cites W2114391755 @default.
- W4378528691 cites W2119036034 @default.
- W4378528691 cites W2120711134 @default.
- W4378528691 cites W2122563776 @default.
- W4378528691 cites W2128153823 @default.
- W4378528691 cites W2129560659 @default.
- W4378528691 cites W2130206051 @default.
- W4378528691 cites W2140594570 @default.
- W4378528691 cites W2148890166 @default.
- W4378528691 cites W2149208048 @default.
- W4378528691 cites W2156618001 @default.
- W4378528691 cites W2160145914 @default.
- W4378528691 cites W2160605010 @default.
- W4378528691 cites W2163509101 @default.